Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study

OBJECTIVE: After surgery, when somatostatin analogs (SAs) do not normalise IGF-I, pegvisomant (PEG) is indicated. Our aim was to define the medical reasons for the treatment of patients with PEG as monotherapy (M) or combined with SA, either as primary bitherapy, PB (PEG is secondarily introduced af...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuhn, Emmanuelle, Caron, Philippe, Delemer, Brigitte, Raingeard, Isabelle, Lefebvre, Hervé, Raverot, Gérald, Cortet-Rudelli, Christine, Desailloud, Rachel, Geffroy, Clementine, Henocque, Robin, Brault, Yves, Brue, Thierry, Chanson, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7835180/
https://www.ncbi.nlm.nih.gov/pubmed/32986202
http://dx.doi.org/10.1007/s12020-020-02501-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7835180/
https://www.ncbi.nlm.nih.gov/pubmed/32986202
http://dx.doi.org/10.1007/s12020-020-02501-3

Ejemplares similares